RecallHawk

SUFLAVE (POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, AND SODIUM CHLORIDE FOR ORA...

AZURITY

Summary

FDA approved SUFLAVE (POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, AND SODIUM CHLORIDE FOR ORAL SOLUTION) by AZURITY. NDA (New Drug) approval (Type 4 - New Combination) on 2023-06-15. FOR SOLUTION, ORAL.

Details

Source

Drug Approval

External ID

NDA215344-1

Action Date

2023-06-15

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

SUFLAVE (generic: POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, AND SODIUM CHLORIDE FOR ORAL SOLUTION), FOR SOLUTION, ORAL. Application: NDA215344

Company

Context & Analysis

AZURITY has 21 FDA actions in our database.

Frequently Asked Questions

How often does AZURITY have FDA actions?

AZURITY has 21 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA215344-1" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions